source
- Vera Therapeutics' Trutakna shows kidney function stabilization and lower death risk in Phase 3 IgAN trialVera Therapeutics reported that its drug Trutakna met its primary goals in a two‑year Phase 3 study of patients with IgA nephropathy. The therapy stabilized kidney function and lowered the risk of…
- Johnson & Johnson’s depression drug JNJ-5120 fails primary endpoint in phase 2 trialA phase 2 study of JNJ-5120, an M1 receptor antagonist developed by Johnson & Johnson with Contineum Therapeutics, did not meet its primary efficacy endpoint in patients with major depressive disor…